The objective of this registry study was to analyse the outcome of patients who underwent allogeneic or autologous haematopoietic stem cell transplantation (HSCT) for hepatosplenic T-cell lymphoma (HSTL), a rare and extremely aggressive peripheral T-cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. Seventy-six patients were identified in the European Society for Bone and Marrow Transplantation database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.

] EBMT Lymphoma Working Party Paris France [2] BMT Department Fundeni Clinical Institute Fundeni Hospital Bucharest Romania

] EBMT Lymphoma Working Party Paris France [2] Department of Hematology and Stem Cell Transplantation Asklepios Klinik St Georg Hamburg Germany

] EBMT Lymphoma Working Party Paris France [2] Department of Medicine University of Heidelberg Heidelberg Germany

] EBMT Lymphoma Working Party Paris France [2] Servei d' Hematologia Institut Catala d'Oncologia Hospital Duran i Reynals Barcelona Spain

CHU Bordeaux Bordeaux France

EBMT Lymphoma Working Party Paris France

Gazi Universitesi Tip Fakultesi Ankara Turkey

Humanitas Cancer Center Rozzano Italy

Institut Paoli Calmettes Marseille France

Institute of Hematology and Blood Transfusion Prague Czech Republic

Pathodiagnostik Berlin Berlin Germany

St James's Hospital Dublin Ireland

University College London Hospital London UK

000      

00000naa a2200000 a 4500

001      

bmc15023024

003      

CZ-PrNML

005      

20150729093930.0

007      

ta

008      

150709s2015 enk f 000 0|eng||

009      

AR

024    7_

$a 10.1038/leu.2014.280 $2 doi

035    __

$a (PubMed)25234166

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Tanase, A $u 1] EBMT Lymphoma Working Party, Paris, France [2] BMT Department, Fundeni Clinical Institute, Fundeni Hospital, Bucharest, Romania.

245    10

$a Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party / $c A. Tanase, N. Schmitz, H. Stein, A. Boumendil, H. Finel, L. Castagna, D. Blaise, N. Milpied, G. Sucak, A. Sureda, K. Thomson, E. Vandenberghe, A. Vitek, P. Dreger, . ,

520    9_

$a The objective of this registry study was to analyse the outcome of patients who underwent allogeneic or autologous haematopoietic stem cell transplantation (HSCT) for hepatosplenic T-cell lymphoma (HSTL), a rare and extremely aggressive peripheral T-cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. Seventy-six patients were identified in the European Society for Bone and Marrow Transplantation database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.

650    _2

$a mladiství $7 D000293

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a kooperační chování $7 D003299

650    _2

$a databáze faktografické $7 D016208

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a následné studie $7 D005500

650    12

$a transplantace hematopoetických kmenových buněk $7 D018380

650    _2

$a lidé $7 D006801

650    _2

$a nádory jater $x mortalita $x patologie $x terapie $7 D008113

650    _2

$a periferní T-buněčný lymfom $x mortalita $x patologie $x terapie $7 D016411

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a recidiva $7 D012008

650    12

$a registrace $7 D012042

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a nádory sleziny $x mortalita $x patologie $x terapie $7 D013160

650    _2

$a analýza přežití $7 D016019

650    _2

$a autologní transplantace $7 D014182

650    _2

$a homologní transplantace $7 D014184

650    _2

$a výsledek terapie $7 D016896

651    _2

$a Evropa $7 D005060

655    _2

$a časopisecké články $7 D016428

700    1_

$a Schmitz, N $u 1] EBMT Lymphoma Working Party, Paris, France [2] Department of Hematology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.

700    1_

$a Stein, H $u Pathodiagnostik Berlin, Berlin, Germany.

700    1_

$a Boumendil, A $u EBMT Lymphoma Working Party, Paris, France.

700    1_

$a Finel, H $u EBMT Lymphoma Working Party, Paris, France.

700    1_

$a Castagna, L $u Humanitas Cancer Center, Rozzano, Italy.

700    1_

$a Blaise, D $u Institut Paoli Calmettes, Marseille, France.

700    1_

$a Milpied, N $u CHU Bordeaux, Bordeaux, France.

700    1_

$a Sucak, G $u Gazi Universitesi Tip Fakultesi, Ankara, Turkey.

700    1_

$a Sureda, A $u 1] EBMT Lymphoma Working Party, Paris, France [2] Servei d' Hematologia, Institut Catala d'Oncologia- Hospital Duran i Reynals, Barcelona, Spain.

700    1_

$a Thomson, K $u University College London Hospital, London, UK.

700    1_

$a Vandenberghe, E $u St James's Hospital, Dublin, Ireland.

700    1_

$a Vitek, A $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.

700    1_

$a Dreger, P $u 1] EBMT Lymphoma Working Party, Paris, France [2] Department of Medicine, University of Heidelberg, Heidelberg, Germany.

700    1_

$a ,

773    0_

$w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 29, č. 3 (2015), s. 686-8

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25234166 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20150709 $b ABA008

991    __

$a 20150729094016 $b ABA008

999    __

$a ok $b bmc $g 1083363 $s 906017

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 29 $c 3 $d 686-8 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138

LZP    __

$a Pubmed-20150709